Literature DB >> 17854943

Beta-cell replacement and regeneration: Strategies of cell-based therapy for type 1 diabetes mellitus.

C Limbert1, G Päth, F Jakob, J Seufert.   

Abstract

Pancreatic islet transplantation has demonstrated that long-term insulin independence may be achieved in patients suffering from diabetes mellitus type 1. However, because of limited availability of islet tissue, new sources of insulin producing cells that are responsive to glucose are required. Development of pancreatic beta-cell lines from rodent or human origin has progressed slowly in recent years. Current experiments for ex vivo expansion of beta cells and in vitro differentiation of embryonic and adult stem cells into insulin producing beta-cell phenotypes led to promising results. Nevertheless, the cells generated to date lack important characteristics of mature beta cells and generally display reduced insulin secretion and loss of proliferative capacity. Therefore, much better understanding of the mechanisms that regulate expansion and differentiation of stem/progenitor cells is necessary. Here, we review recent advances in the identification of potential cellular sources, and the development of strategies to regenerate or fabricate insulin producing and glucose sensing cells that might enable future cell-based therapies of diabetes mellitus type 1.

Entities:  

Mesh:

Year:  2007        PMID: 17854943     DOI: 10.1016/j.diabres.2007.06.016

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  12 in total

Review 1.  The quest for tissue stem cells in the pancreas and other organs, and their application in beta-cell replacement.

Authors:  Isabelle Houbracken; Luc Bouwens
Journal:  Rev Diabet Stud       Date:  2010-08-10

2.  miR-25 and miR-92a regulate insulin I biosynthesis in rats.

Authors:  Dwi Setyowati Karolina; Sugunavathi Sepramaniam; Hui Zhing Tan; Arunmozhiarasi Armugam; Kandiah Jeyaseelan
Journal:  RNA Biol       Date:  2013-08       Impact factor: 4.652

3.  The prospect of induced pluripotent stem cells for diabetes mellitus treatment.

Authors:  Andreas Soejitno; Pande Kadek Aditya Prayudi
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

4.  Genetic inducible fate mapping in larval zebrafish reveals origins of adult insulin-producing β-cells.

Authors:  Yiyun Wang; Meritxell Rovira; Shamila Yusuff; Michael J Parsons
Journal:  Development       Date:  2011-01-05       Impact factor: 6.868

5.  Non-β-cell progenitors of β-cells in pregnant mice.

Authors:  Sylvie Abouna; Robert W Old; Stella Pelengaris; David Epstein; Vasiliki Ifandi; Ian Sweeney; Michael Khan
Journal:  Organogenesis       Date:  2010 Apr-Jun       Impact factor: 2.500

Review 6.  Autologous umbilical cord blood infusion for type 1 diabetes.

Authors:  Michael J Haller; Hilla-Lee Viener; Clive Wasserfall; Todd Brusko; Mark A Atkinson; Desmond A Schatz
Journal:  Exp Hematol       Date:  2008-03-20       Impact factor: 3.084

Review 7.  Promoting ectopic pancreatic fates: pancreas development and future diabetes therapies.

Authors:  E J Pearl; M E Horb
Journal:  Clin Genet       Date:  2008-09-09       Impact factor: 4.438

8.  Peripheral blood monocytes can differentiate into efficient insulin-producing cells in vitro.

Authors:  A Kyventidis; G Tzimagiorgis; T Didangelos
Journal:  Hippokratia       Date:  2015 Oct-Dec       Impact factor: 0.471

Review 9.  Can we learn from viruses how to prevent type 1 diabetes?: the role of viral infections in the pathogenesis of type 1 diabetes and the development of novel combination therapies.

Authors:  Matthias von Herrath
Journal:  Diabetes       Date:  2009-01       Impact factor: 9.461

10.  Autologous umbilical cord blood transfusion in very young children with type 1 diabetes.

Authors:  Michael J Haller; Clive H Wasserfall; Kieran M McGrail; Miriam Cintron; Todd M Brusko; John R Wingard; Susan S Kelly; Jonathan J Shuster; Mark A Atkinson; Desmond A Schatz
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.